lunes, 31 de marzo de 2014

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA : Nature Medicine : Nature Publishing Group

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA : Nature Medicine : Nature Publishing Group



Clinical validation of the detection of KRAS andBRAF mutations from circulating tumor DNA

Nature Medicine
 
 
doi:10.1038/nm.3511
Received
 
Accepted
 
Published online
 

Abstract

Assessment of KRAS status is mandatory in patients with metastatic colorectal cancer (mCRC) before applying targeted therapy. We describe here a blinded prospective study to compare KRASand BRAF mutation status data obtained from the analysis of tumor tissue by routine gold-standard methods and of plasma DNA using a quantitative PCR–based method specifically designed to analyze circulating cell-free DNA (cfDNA). The mutation status was determined by both methods from 106 patient samples. cfDNA analysis showed 100% specificity and sensitivity for the BRAFV600E mutation. For the seven tested KRAS point mutations, the method exhibited 98% specificity and 92% sensitivity with a concordance value of 96%. Mutation load, expressed as the proportion of mutant alleles in cfDNA, was highly variable (0.5–64.1%, median 10.5%) among mutated samples. CfDNA was detected in 100% of patients with mCRC. This study shows that liquid biopsy through cfDNA analysis could advantageously replace tumor-section analysis and expand the scope of personalized medicine for patients with cancer.

No hay comentarios:

Publicar un comentario